Peter P. Lee, MD: Publications
Selected publications (as of March 2004)
- Lee PP , Zeng D, MaCaulay AE, Chen YF, Geiler C, Umetsu DT, and Chao NJ. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood 90(4):1611-1617, 1997.
- Yee C, Savage PA, Lee PP, Davis MM, and Greenberg PD. Isolation of high-avidity melanoma-reactive CTL from heterogenous populations using peptide-MHC tetramers. Journal of Immunology 162(4):2227-2234, 1999.
- Molldrem JJ, Lee PP, Wang C, Champlin RE, and Davis MM. A HLA-A2-PR1 tetramer can be used to isolate low-frequency CTL from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Research, 59(11):2675-2681, 1999.
- Lee PP , Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, and Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Medicine, 5(6):677-685, 1999.
- Hernandez J, Lee PP, Davis MM, and Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self-tolerance on the T cell receptor repertoire. Journal of Immunology 164(2):596-602, 2000.
- Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, and Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine, 6(8):1018-1023, 2000.
- Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell, SR, and Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. Journal of Experimental Medicine, 192(11):1637-1644, 2000.
- Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, and Enk AH. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. International Journal of Cancer, 93(2):243-51, 2001.
- Lee PP , Wang F, Kuniyoshi J, Rubio V, Stuge T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, and Weber J. Effects of Interleukin-12 on the immune response to a multi-peptide vaccine for resected metastatic melanoma. Journal of Clinical Oncology, 19(7):3836-3847, 2001.
- Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, and Atkins MB. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the society for biological therapy. J Immunotherapy 25(2):97-138, 2002.
- Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, and Mule JJ. A Phase I Trial of Tumor Lysate-pulsed Dendritic Cells in the Treatment of Advanced Cancer. Clin Cancer Res 8(4):1021-1032, 2002.
- Falco DA, Nepomuceno RR, Krams SM, Lee PP, Davis MM, Salvatierra O, Alexander SR, Esquivel CO, Cox KL, Frankel LR, Martinez OM. Identification of Epstein-Barr virus-specific CD8+ T lymphocytes in the circulation of pediatric transplant recipients. Transplantation 74(4):501-510, 2002.
- Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, and Lee PP. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97(1):186-200, 2003.
- Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, and Davis MM. Chronic Myelogenous Leukemia Shapes Host Immunity by Selective Deletion of High Avidity Leukemia-Specific T Cells. Journal of Clinical Investigation, 111:639-647, 2003.
- Chang T, Chang C, Simpson D, Xu Q, Martin P, Lagenaur L, Schoolnik G, Ho D, Hillier S, Holodniy M, Lewicki J, and Lee PP. Inhibition of HIV Infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proceedings of the National Academy of Science 100(20):11672-11677, 2003.
- Pullarkat V, Lee PP, Scotland R, Rubio V, Groshen S, Gee C, Lau R, Snively J, Sian S, Woulfe SL, Wolfe RA, Weber JS. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res. Apr;9(4):1301-12, 2003
- Rubio V, Stuge T, Singh N, Betts M, Weber J, Roederer M, and Lee PP. Ex Vivo Identification, Isolation, and Analysis of Tumor-Cytolytic T cells. Nature Medicine 9(11):1377-1382, 2003.
- Xu T, Shen C, Deng D, Ilsley D, Weber J, Holmes S, and Lee PP. Subtle but Statistically Significant Gene Expression Differences in T Cells from Melanoma Patients versus Healthy Donors. Cancer Research, accepted.
- Casal A, Alber M, Sumen C, Reddy T, and Lee PP. Agent-Based Modeling of the Context Dependency in T Cell Recognition. Submitted.
- Stuge T, Holmes S, Rubio V, Sadharan S, Roederer M, Weber J, and Lee PP. Significance and Optimization of Recognition Efficiency for T Cell Response to Cancer. Submitted.
Cited References
- Yannelli JR, Hyatt C, McConnell S, et al., Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. International Journal of Cancer, 1996. 65(4): p. 413-21.
- Topalian SL, Solomon D, and Rosenberg SA, Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. Journal of Immunology, 1989. 142(10): p. 3714-25.
- Lee PP, Yee C, Savage PA, et al., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Medicine, 1999. 5(6): p. 677-85.
- Sahin U, Türeci O, Schmitt H, et al., Human neoplasms elicit multiple specific immune responses in the autologous host. Proceedings of the National Academy of Sciences of the United States of America, 1995. 92(25): p. 11810-3.
- Rosenberg SA, Kawakami Y, Robbins PF, et al., Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Advances in Cancer Research, 1996. 70(1): p. 145-77.
- Boon T, Coulie P, Marchand M, et al., Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Advances in Oncology, 1994. 130(1): p. 53-69.
- Pardoll DM, Inducing autoimmune disease to treat cancer. Proceedings of the National Academy of Sciences of the United States of America, 1999. 96(10): p. 5340-2.
- Lee KH, Wang E, Nielsen MB, et al., Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. Journal of Immunology, 1999. 163(11): p. 6292-300.
- Osanto S, Schiphorst PP, Weijl NI, et al., Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Human Gene Therapy, 2000. 11(5): p. 739-50.
- Ranieri E, Kierstead LS, Zarour H, et al., Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunological Investigations, 2000. 29(2): p. 121-5.
- Kim JA, Bresler HS, Martin EW, Jr., et al., Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody. Cancer, 1999. 86(1): p. 22-30.
- Figlin RA, Pierce WC, Kaboo R, et al., Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. Journal of Urology, 1997. 158(3 Pt 1): p. 740-5.
- Chang AE, Aruga A, Cameron MJ, et al., Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. Journal of Clinical Oncology, 1997. 15(2): p. 796-807.
- Molldrem JJ, Lee PP, Wang C, et al., Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nature Medicine, 2000. 6(9): p. 1018-23.
- Natali PG, Nicotra MR, Bigotti A, et al., Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 1989. 86(17): p. 6719-23.
- Maeurer MJ, Gollin SM, Martin D, et al., Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. Journal of Clinical Investigation, 1996. 98(7): p. 1633-41.
- Lahat N, Rahat MA, Sadeh O, et al., Regulation of HLA-DR and costimulatory B7 molecules in human thyroid carcinoma cells: differential binding of transcription factors to the HLA-DRalpha promoter. Thyroid, 1998. 8(5): p. 361-9.
- Barth RJ, Jr., Camp BJ, Martuscello TA, et al., The cytokine microenvironment of human colon carcinoma. Lymphocyte expression of tumor necrosis factor-alpha and interleukin-4 predicts improved survival. Cancer, 1996. 78(6): p. 1168-78.
- Yanagisawa K, Osada H, Masuda A, et al., Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-beta in human normal lung epithelial cells. Oncogene, 1998. 17(13): p. 1743-7.
- Hahne M, Rimoldi D, Schröter M, et al., Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape [see comments]. Science, 1996. 274(5291): p. 1363-6.
- Müller M, Strand S, Hug H, et al., Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. Journal of Clinical Investigation, 1997. 99(3): p. 403-13.
- Mizoguchi H, O'Shea JJ, Longo DL, et al., Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice [see comments]. Science, 1992. 258(5089): p. 1795-8.
- Ochoa AC and Longo DL, Alteration of signal transduction in T cells from cancer patients. Important Advances in Oncology, 1995. 55(17): p. 43-54.
- Finke JH, Zea AH, Stanley J, et al., Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Research, 1993. 53(23): p. 5613-6.
- Nakagomi H, Petersson M, Magnusson I, et al., Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Research, 1993. 53(23): p. 5610-2.
- Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 1998. 95(3): p. 1178-83.
- Fischer B, Müller B, Fischer KG, et al., Acidic pH inhibits non-MHC-restricted killer cell functions. Clinical Immunology, 2000. 96(3): p. 252-63.
- McKallip R, Li R, and Ladisch S, Tumor gangliosides inhibit the tumor-specific immune response. Journal of Immunology, 1999. 163(7): p. 3718-26.
- Otsuji M, Kimura Y, Aoe T, et al., Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 1996. 93(23): p. 13119-24.
Back to: Peter P. Lee Laboratory
